AXSM (Axsome Therapeutics) Growth Rank : 0 (As of Apr. 08, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics Growth Rank?

Axsome Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Axsome Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

0HKF:UK 19X:Germany

Address

One World Trade Center, 22nd Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Executives

Nick Pizzie	officer: Chief Financial Officer	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad	director	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Mark L. Jacobson	officer: Chief Operating Officer	200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
Mark Coleman	director	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Roger Jeffs	director
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Hunter R. Murdock	officer: General Counsel	22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Herriot Tabuteau	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
David C Marek	officer: Chief Commercial Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski	officer: Chief Financial Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye	officer: Chief Medical Officer	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance	officer: Vice President, Finance	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc	10 percent owner	630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111